Bari, Italy

Elvira Favoino



 

Average Co-Inventor Count = 5.0

ph-index = 2

Forward Citations = 8(Granted Patents)


Location History:

  • Casamassima Bari, IT (2016)
  • Bari, IT (2013 - 2021)

Company Filing History:


Years Active: 2013-2021

Loading Chart...
Loading Chart...
Loading Chart...
6 patents (USPTO):Explore Patents

Title: Elvira Favoino: Innovator in Monoclonal Antibodies

Introduction

Elvira Favoino is a prominent inventor based in Bari, Italy. She has made significant contributions to the field of biotechnology, particularly in the development of monoclonal antibodies. With a total of 6 patents to her name, her work has the potential to impact cancer treatment and diagnostics.

Latest Patents

Favoino's latest patents focus on isolated monoclonal antibodies that specifically bind to endoplasmin. These antibodies are noteworthy for being fully human in some embodiments. The patents also disclose recombinant nucleic acids encoding these antibodies, expression vectors that include these nucleic acids, and host cells transformed with these vectors. The disclosed antibodies are particularly useful for detecting and treating tumors that express endoplasmin, including melanoma, breast cancer, and several other types of cancer. One specific example highlighted in her patents is the application of these antibodies in treating melanoma.

Career Highlights

Elvira Favoino is affiliated with the University of Pittsburgh, where she continues her research and development in the field of monoclonal antibodies. Her innovative work has garnered attention in the scientific community, contributing to advancements in cancer therapies.

Collaborations

Favoino has collaborated with notable colleagues, including Soldano Ferrone and Xinhui Wang. Their combined expertise enhances the research and development of effective cancer treatments.

Conclusion

Elvira Favoino's contributions to the field of biotechnology, particularly through her patents on monoclonal antibodies, demonstrate her commitment to advancing cancer treatment. Her work not only showcases her innovative spirit but also holds promise for improving patient outcomes in oncology.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…